BidaskClub lowered shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) from a hold rating to a sell rating in a research report released on Sunday.

VRX has been the subject of several other reports. Wells Fargo & Company dropped coverage on shares of Valeant Pharmaceuticals International in a research note on Sunday, July 30th. Scotiabank cut their price objective on shares of Valeant Pharmaceuticals International from $15.00 to $12.00 and set a sector perform rating for the company in a research report on Wednesday, April 26th. Vetr downgraded shares of Valeant Pharmaceuticals International from a strong-buy rating to a buy rating and set a $14.82 price objective for the company. in a research report on Monday, May 22nd. Mizuho restated an underperform rating and set a $8.00 price objective (down from $9.00) on shares of Valeant Pharmaceuticals International in a research report on Monday, April 17th. Finally, Canaccord Genuity set a $12.00 price objective on shares of Valeant Pharmaceuticals International and gave the stock a hold rating in a research report on Monday, May 8th. Four investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of $16.96.

Valeant Pharmaceuticals International (NYSE VRX) opened at 15.64 on Friday. Valeant Pharmaceuticals International has a 1-year low of $8.31 and a 1-year high of $32.74. The stock has a 50 day moving average price of $16.44 and a 200-day moving average price of $13.39. The company’s market capitalization is $5.44 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.87 by $1.93. Valeant Pharmaceuticals International had a negative net margin of 14.96% and a positive return on equity of 58.02%. The business had revenue of $2.11 billion during the quarter, compared to the consensus estimate of $2.17 billion. During the same period last year, the business posted ($1.08) EPS. Valeant Pharmaceuticals International’s revenue was down 11.1% on a year-over-year basis. Equities analysts predict that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Cut to Sell at BidaskClub” was published by Daily Political and is the property of of Daily Political. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/08/09/valeant-pharmaceuticals-international-inc-nysevrx-cut-to-sell-at-bidaskclub.html.

In other news, Director Schutter Richard U. De acquired 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 11th. The shares were acquired at an average cost of $13.90 per share, with a total value of $278,000.00. Following the completion of the purchase, the director now directly owns 70,572 shares of the company’s stock, valued at approximately $980,950.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 5.87% of the company’s stock.

Several hedge funds have recently bought and sold shares of VRX. ValueAct Holdings L.P. boosted its stake in Valeant Pharmaceuticals International by 20.0% in the first quarter. ValueAct Holdings L.P. now owns 17,997,224 shares of the specialty pharmaceutical company’s stock worth $198,509,000 after buying an additional 3,002,963 shares during the last quarter. Vanguard Group Inc. boosted its stake in Valeant Pharmaceuticals International by 9.8% in the first quarter. Vanguard Group Inc. now owns 6,980,074 shares of the specialty pharmaceutical company’s stock worth $76,990,000 after buying an additional 621,618 shares during the last quarter. Bank of Montreal Can boosted its stake in Valeant Pharmaceuticals International by 9.8% in the second quarter. Bank of Montreal Can now owns 6,330,670 shares of the specialty pharmaceutical company’s stock worth $109,521,000 after buying an additional 564,215 shares during the last quarter. OppenheimerFunds Inc. boosted its stake in Valeant Pharmaceuticals International by 17.1% in the first quarter. OppenheimerFunds Inc. now owns 4,489,169 shares of the specialty pharmaceutical company’s stock worth $49,516,000 after buying an additional 656,116 shares during the last quarter. Finally, Morgan Stanley boosted its stake in Valeant Pharmaceuticals International by 48.2% in the first quarter. Morgan Stanley now owns 2,777,063 shares of the specialty pharmaceutical company’s stock worth $30,631,000 after buying an additional 903,256 shares during the last quarter. 51.14% of the stock is currently owned by hedge funds and other institutional investors.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.